Skip to content

News

OCRA-Funded Research Identifies New “Master” Drug Targets for Ovarian Cancer

OCRA-Funded Research Identifies New “Master” Drug Targets for Ovarian Cancer

An interdisciplinary group of researchers from around the country analyzed tumor samples from nearly 10,000 patients with 34 types of cancer to reveal unique genetic switches associated with each tumor type. The research, published in Science Advances and supported by multiple OCRA grants, turned up three potential drug targets for aggressive ovarian cancer, among other findings.  Scientists … Continued

Liya Ding, PhD | Meet a Scientist

Liya Ding, PhD | Meet a Scientist

Dr. Liya Ding, of Dana-Farber Cancer Institute, is a 2021 recipient of OCRA’s Liz Tilberis Early Career Award. With her project, “Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer,” Dr. Ding is focusing on PARP inhibitors — some of the most effective drug therapies available for ovarian cancer, but that often come with a … Continued

FDA Approves Drug to Identify Ovarian Cancer Lesions During Surgery

FDA Approves Drug to Identify Ovarian Cancer Lesions During Surgery

In what could prove to be a game-changer for ovarian cancer debulking procedures, the U.S. Food and Drug Administration (FDA) has approved Cytalux (pafolacianine), an imaging drug designed to help doctors better locate and identify ovarian cancer lesions during surgery. The drug, which is administered via injection at the time of surgery, works by binding … Continued

Bojana Stefanovska, PhD | Meet a Scientist

Bojana Stefanovska, PhD | Meet a Scientist

Dr. Bojana Stefanovska, at University of Minnesota Twin Cities, is a 2021 recipient of OCRA’s Ann and Sol Schreiber Mentored Investigator Award. Her project, “APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC,” explores DNA repair as a potential treatment avenue for clear cell ovarian carcinoma (CCOC). What initially sparked your interest in science? … Continued

The Overview: November 2021

The Overview: November 2021

As we head into the Thanksgiving holiday, we have much to be thankful for … an embracing and strong survivor community, supporters who remain ever committed to the cause, and brilliant grantees who are making strides every day in the search for better treatments and a cure for ovarian cancer. Here’s a roundup of what’s … Continued

OCRA-Funded Study Points to New Approach to Improve Ovarian Cancer Treatment

OCRA-Funded Study Points to New Approach to Improve Ovarian Cancer Treatment

The following is a press release from University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, and Magee-Womens Research Institute PITTSBURGH, Nov. 12, 2021 – Immune checkpoint inhibitors are a type of cancer treatment that help the immune system’s T cells recognize and attack tumors. But these immunotherapy drugs aren’t effective against all cancers. In … Continued

The Overview: October 2021

The Overview: October 2021

Have we got a roundup in store! You heard from us a lot in September (thanks to you, we surpassed our Ovarian Cancer Awareness Month fundraising goal!) and there’s still so much to report … research progress, a brand new clinical trial initiative, our upcoming Fall Advocacy Day, and the list goes on. Read on … Continued

Finding the Story in the Data | Meet a Scientist

Finding the Story in the Data | Meet a Scientist

Sridevi Challa, PhD, an OCRA grantee at UT Southwestern, is on the receiving end of some major accolades. She is the lead author of a study that dozens of news outlets are describing as having found the “Achilles’ Heel” of ovarian cancer cells. This opens the door for new research in biomarkers and the development … Continued

OCRA-Funded Study Identifies Role of Deubiquitinating Enzyme in Ovarian Cancer Progression

OCRA-Funded Study Identifies Role of Deubiquitinating Enzyme in Ovarian Cancer Progression

OCRA grantee Dr. Sumegha Mitra of Indiana University and colleagues have identified the mechanism by which a specific deubiquitinating enzyme known as UCHL1 promotes the growth of high-grade serous ovarian cancer in some patients. This discovery may aid in the development of future ovarian cancer therapies, as it points to the potential effectiveness of a targeted inhibitor … Continued

Groundbreaking Initiative Seeks to Accelerate Development of New Treatments with OCRA’s Support

Groundbreaking Initiative Seeks to Accelerate Development of New Treatments with OCRA’s Support

LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to test multiple drugs simultaneously against the standard of care treatments to rapidly test and deliver new therapies to patients with advanced ovarian cancer or recurrent … Continued

The Overview: August 2021

The Overview: August 2021

As we count down to Ovarian Cancer Awareness Month and our virtual National Conference, there are so many ways to get involved … whether by learning more and connecting with others or raising awareness of the disease and vital funds for research. Read on to find out how you can be a voice, and a … Continued

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.